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Abstract
An 84-year-old woman underwent hysterectomy due to a friable endometrial mass infiltrating
almost half way through the myometrial wall. The tumor consisted of papillary structures with thin
fibrovascular cores covered by several layers of pleomorphic cells. The deeply located neoplastic
cells were ovoid with a pale eosinophilic cytoplasm resembling urothelial cells. A diagnosis of
papillary squamous cell carcinoma of the endometrium with transitional cell differentiation was
made. Although she recovered well after surgery, she died one year later because of disseminated
disease. In an attempt to obtain new insights into the physiopathology of this very rare tumor, an
immunohistochemical panel with 32 markers was performed. The neoplastic cells were positive for
cytokeratin 5, vimentin, p63, p21, VEGF, Ki67, BAG1, and bcl-2. The expression of BAG-1 and bcl-
2 may suggest that anti-apoptotic stimuli are preponderant in this neoplasm.
Background
Primary squamous cell carcinoma (SCC) of the
endometrium is uncommon, with only about seventy
cases reported in the literature [1]. Its histological appear-
ance is identical to that of SCC of the uterine cervix [1]. A
transitional cell carcinoma of the endometrium is a carci-
noma in which 90% of more of the neoplastic cells resem-
ble the urothelial transitional cells. Lower transitional cell
differentiation qualifies the tumor as a mixed carcinoma
with transitional cell differentiation [2,3]. Transitional
cell differentiation in endometrial carcinomas is
extremely uncommon, with fewer than 15 cases reported
[2,3]. In an attempt to obtain new insights into the phys-
iopathology of this very rare tumor, an immunohisto-
chemical panel was applied to a papillary SCC of the
endometrium with transitional cell differentiation.
Case presentation
An 84-year-old woman gravida 7 para 4, whose last nor-
mal menstrual period was 35 years ago, presented with
postmenopausal bleeding and pelvic pain of 2 months
duration. She denied any use of estrogen replacement
therapy or any history of previous abnormal vaginal
bleeding. Past medical history showed arterial hyperten-
sion under medical control. She had no previous history
of lower urinary tract cancer. Her general physical exami-
nation was within normal limits. The pelvic examination,
however, showed that the uterus was slightly enlarged for
her age. The ovaries were not palpable. Gross examination
of the cervix did not show any lesion.
An endometrial biopsy was performed and the diagnosis
of SCC was made. A preoperative bone scan and a chest
radiograph were normal. She underwent abdominal sur-
gery consisting of total hysterectomy with bilateral salp-
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ingo-oophorectomy. There was no grossly apparent
tumor on exploration of the abdomen. Pelvic washing
was also performed, with cytological examination being
negative for neoplastic cells.
The patient recovered well after surgery; however she died
one year later due to generalized metastasis. An autopsy
was not performed.
Pathological findings
The resected uterus was irregularly enlarged and weighed
120 g. The endometrial cavity showed a 5 × 3 × 3 cm fria-
ble mass infiltrating almost half way through the myome-
trial wall. The surgical specimen was fixed in 4% formalin
and sequential 3 mm sections were obtained throughout
the specimen. All sections obtained from the tumoral
mass were embedded in paraffin and 4 µm histological
sections obtained from paraffin-embedded blocks were
stained with hematoxylin-eosin. For immunohistochemi-
cal staining the paraffin-embedded blocks were cut into 3
µm sections, deparaffinized, and rehydrated. A standard
avidin-biotin-peroxidase method was used (Novostain
Super ABC kit, Novocastra, Newcastle upon Tyne, UK).
The antibodies and the dilutions are specified in Table 1.
Slides stained with hematoxylin-eosin showed a tumor
consisting of papillary structures with thin fibrovascular
cores covered by several cell layers with large amounts of
cytoplasm and pleomorphic and hypercromatic nuclei
(Fig. 1). The nucleoli were easily visualized. Mitoses were
scarce. Keratinization was inconspicuous. The invasive
front of the tumor was of the pushing type and the deeply
located neoplastic cells were ovoid with a pale eosi-
nophilic cytoplasm, resembling urothelial cells (Fig. 2).
These cells represented 15% of the total tumor volume. A
diagnosis of papillary squamous cell carcinoma with foci
of transitional cell differentiation was made. The adjacent
non-neoplastic endometrium exhibited an intense xan-
thogranulomatous reaction. There was an abrupt change
between the tumor and the endometrium. There were also
sparse foci of vascular lymph space invasion. The tumor
did not reach the cervix or the adnexa which were entirely
examined microscopically.
The immunohistochemistry study showed that more than
10% of the neoplastic cells were positive for BAG1, p21,
VEGF and vimentin. The basal cells of the neoplastic epi-
thelium stained diffusely for bcl-2 (80% of the cells). Ki67
stained 15% of neoplastic cells. Contrary to normal squa-
mous tissue used as positive control, in which p63 stained
only the basal cells, the squamous component of the car-
cinoma stained diffusely for p63 throughout the thickness
of the epithelium (more than 90% of the cells) (Fig. 3).
Cytokeratin 5 was diffusely positive in the squamous
component and negative in the transitional cell areas. On
Transitional cell-like component of the tumor showing neo- plastic cells with pale eosinophilic cytoplasm (hematoxylin  and eosin, ×400) Figure 2
Transitional cell-like component of the tumor showing neo-
plastic cells with pale eosinophilic cytoplasm (hematoxylin 
and eosin, ×400).
Squamous cell component showing fibrovascular cores cov- ered with several layers of neoplastic cells (hematoxylin and  eosin, ×200) Figure 1
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the other hand, cytokeratins 8/18 were focally positive in
the transitional cells (30% of the cells) but negative in the
squamous areas. Both cytokeratins 7 and 20 were nega-
tive. The nuclei were diffusely positive for Chk2 and p27,
which is considered to be the normal staining pattern for
these markers. The other markers were negative.
Discussion
An extension into the endometrium from a primary SCC
of the cervix must be ruled out before making a diagnosis
of pure SSC of the endometrium because this situation is
far more common [4]. Besides, considering that pure
squamous cell carcinoma of the endometrium is rare and
a mixed endometrioid component may be focal, the
tumor was entirely examined microscopically to rule out
endometrioid carcinoma with extensive squamotransi-
tional cell differentiation. The present case satisfied the
three major criteria for the diagnosis of primary SCC of
the endometrium: no glandular component was found
after extensive sampling, the cervix was ruled out as the
primary site, and there was no connection between the
tumor and the stratified squamous epithelium of the cer-
vix [4]. As observed in the present case, SCC of the
endometrium usually occurs in postmenopausal women.
Most patients undergo total abdominal hysterectomy and
bilateral salpingo-oophorectomy followed or not by adju-
vant radiation therapy [4]. The prognosis is poor, with the
overall survival ranging from 3 to 42 months [4]. The
patient of this report died 12 months after the surgery
because of disseminated disease.
The diagnosis of transitional cell differentiation is made
based on morphological rather than immunohistochemi-
cal features [2]. The morphological criteria include neo-
plastic cells with a pale eosinophilic cytoplasm
resembling bladder urothelial epithelium [2]. Tumors
with these features are more aggressive than conventional
endometrial carcinomas [4]. All endometrial carcinomas
with transitional cell differentiation are negative for cytok-
eratin 20 (CK20), but half are positive for cytokeratin 7
(CK7) [3]. This immunoprofile supports mullerian rather
than urothelial origin. Some authors have noticed a simi-
larity between the papillary variant of SCC and the transi-
tional cell carcinoma of urothelial origin, but the exact
relationship between them has not been fully elucidated
[5]. In the present study the neoplasm was positive for
cytokeratin 5 and negative for both cytokeratins 7 and 20.
These findings agree with data reported by Stefansson et
al. (2005) who verified that CK5/6 expression is more fre-
quent in endometrioid tumors with squamous differenti-
ation [6].
P63 is a marker of basal and squamous differentiation in
several normal epithelia and human tumors and is con-
sidered to be a marker of progenitor or stem cells in strat-
ified epithelia [6]. Contrary to normal squamous tissue
used as positive control, in which p63 stained only the
basal cells, the squamous component of the carcinoma
stained diffusely for p63 throughout the thickness of the
epithelium. In addition, there is increasing evidence that
p63 may act as an oncogene in the tumorigenesis of
endometrial carcinomas and its expression is significantly
associated with high histologic grade, higher mitotic
count and tumor cell proliferation, Ki-67 expression, mic-
rosatellite instability (MSI) and loss of hMSH6 expression
[6]. These findings may suggest that the present tumor
arose from undifferentiated stem cells, a hypothesis possi-
bly explaining why a pure SCC developed in the
endometrium. This hypothesis, although attractive, is
merely speculative since p63 is frequently seen in various
tumors showing squamous differentiation. In that way,
the p63 immunohistochemical findings in this case may
possibly only indicate that the tumor is of squamous dif-
ferentiation rather than implying cell of origin.
In the present report, the carcinoma's proliferative rate
was 15%, as assessed by the Ki67 labeling index. Ki67,
however, is not considered a prognostic marker in
endometrial carcinomas [7]. The neoplastic cells were
positive for vimentin, p21, and VEGF. Vimentin expres-
sion was expected since it has also been consistently dem-
onstrated in endometrial adenocarcinomas [8]. The
expression of p21 and VEGF in endometrial carcinomas
predicts myometrial invasion and lymph node metastasis
and may prospectively identify patients who are at
increased risk for poor outcome [9,10]. Indeed, in the
P63 expression (nuclear staining) throughout the thickness of  the neoplastic epithelium (immunohistochemistry, ×200) Figure 3
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present report, the patient had an unfavorable outcome.
The tumor suppressor p27 was not down-regulated in the
present case. In endometrial carcinomas, loss of p27
expression may be involved in the tumor progression;
however its down-regulation is not considered a predictor
factor of adverse outcome for these neoplasms [11].
The immunohistochemistry study showed that more than
10% of the neoplastic cells were positive for BAG1 and the
basal cells of the neoplastic epithelium stained diffusely
for bcl-2. Both BAG1 and bcl-2 play a role in the inhibi-
tion of apoptosis in endometrial carcinoma [12]. These
data may suggest that anti-apoptotic stimuli are prepon-
derant in this neoplasm. In endometrial carcinomas, bcl-
2 expression does not provide prognostic information
[13].
In this report, both HPV and p16 were negative, arguing
against a direct role for HPV in the etiology of these neo-
plasms. This finding is in accordance with Lininger et al.
(1997), who found HPV in only one of nine cases they
analyzed [2].
Although the immunohistochemical findings of the
present report are intriguing, no definite conclusions can
be done based in a single case. Further studies with a
larger patient series are needed to confirm the immuno-
histochemical findings in this type of tumor.
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